Clinical Trials Sponsored by ASC Therapeutics

Total 7846 results

ASC Therapeutics

Not yet recruiting

ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Acute-graft-versus-host Disease
ASC Therapeutics

Recruiting

ASC618 Gene Therapy in Hemophilia A Patients

Hemophilia A

United States
Nykode Therapeutics ASA
Vaccibody AS

Completed

A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers

Infections | COVID-19 | Infection Viral

Norway
Nykode Therapeutics ASA
Nektar Therapeutics; Vaccibody AS

Completed

A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer (DIRECT-01)

Locally Advanced or Metastatic Solid Tumours

Germany
Nykode Therapeutics ASA
Theradex; Vaccibody AS

Completed

An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

High Grade Cervical Intraepithelial Neoplasia

Germany
Nykode Therapeutics ASA
Genentech, Inc.; Vaccibody AS

Recruiting

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

Solid Tumors, Adult

United States, Spain, Germany
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

B-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma

United States, Spain, Italy, United Kingdom, Belgium, Czechia
ADC Therapeutics S.A.

Completed

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Puerto Rico
ADC Therapeutics S.A.

Withdrawn

Long-term Registry of Patients Treated With Loncastuximab Tesirine

B-Cell Lymphomas

United States
ADC Therapeutics S.A.

Withdrawn

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) (LOTIS-8)

Diffuse Large B-Cell Lymphoma

United States
ADC Therapeutics S.A.

Terminated

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

Spain, United States
ADC Therapeutics S.A.

Terminated

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Breast Cancer | Non Small Cell Lung Cancer | Bladder Cancer | GastroEsophageal Cancer

United States, Belgium
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
ADC Therapeutics S.A.

Recruiting

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Spain, France
ADC Therapeutics S.A.

Recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

Japan, Belgium, France, Italy, Spain, United Kingdom, United States, Israel, Hungary, Brazil, Switzerland, Poland, Canada, Puerto Rico, Czechia, Netherlands, China, Mexico, Argentina, Chile, Turkey
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States, Spain, United Kingdom, Poland, Belgium, Hungary, Germany, France, Italy, Czechia, Canada
ADC Therapeutics S.A.

Terminated

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

United States, Spain, United Kingdom, France, Italy, Belgium
ADC Therapeutics S.A.

Terminated

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States, Belgium, Hungary, Israel, Spain, Switzerland, Poland, France, United Kingdom, Italy
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B-Cell Lymphoma Refractory

United States, United Kingdom, Italy, Switzerland
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Colo-rectal Cancer | Triple-negative Breast Cancer | Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content | Head and Neck...

United States, Belgium, United Kingdom
ADC Therapeutics S.A.

Terminated

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

Advanced Solid Tumors

United States
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma

Taiwan, Korea, Republic of, United States, Brazil
ADC Therapeutics S.A.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Advanced Solid Tumors

United States, Spain, United Kingdom
ADC Therapeutics S.A.

Completed

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Hodgkin Lymphoma | Non-Hodgkin Lymphoma

United States, United Kingdom
ADC Therapeutics S.A.

Terminated

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia

United States
ADC Therapeutics S.A.

Completed

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell | Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | Burkitt's Lymphoma | Lymphoma, Marginal Zone

United Kingdom, United States, Italy
ADC Therapeutics S.A.

No longer available

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Nykode Therapeutics ASA
Roche Pharma AG; Vaccibody AS

Completed

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

Cervical Cancer | Cervix Cancer

Belgium, Germany, Bulgaria, Czechia, Norway, Poland
EXACT Therapeutics AS

Recruiting

PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin (ACT)

Colorectal Cancer | Solid Tumor

United Kingdom, Norway
IGM Biosciences, Inc.
ADC Therapeutics S.A.

Active, not recruiting

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCL

United States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
University of Miami
ADC Therapeutics S.A.

Recruiting

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma

United States
Fred Hutchinson Cancer Center
ADC Therapeutics

Withdrawn

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent High... and other conditions

United States
Nykode Therapeutics ASA
Merck Sharp & Dohme LLC

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

HNSCC | HPV-Related Squamous Cell Carcinoma

France, Norway, Spain, United Kingdom, Hungary, Poland, Czechia, Germany
Hubro Therapeutics AS
Quotient Sciences

Completed

Safety and Immune Response to FMPV-1

Colorectal Cancer

United Kingdom
University of Birmingham
PSC Support; Life Arc

Not yet recruiting

FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis (FARGO)

Inflammatory Bowel Diseases | Primary Sclerosing Cholangitis

United Kingdom
Nykode Therapeutics ASA
Roche Pharma AG; GOG Foundation

Not yet recruiting

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Cervical Cancer | HPV-Related Malignancy | HPV-Related Cervical Carcinoma
Gwynn Long, M.D.
ADC Therapeutics S.A.

Terminated

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Myeloproliferative Neoplasm (MDS/MPN)

United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19

Severe COVID-19

Israel
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

Differential Thyroid Cancer

United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

Study to Assess VB-201 in Patients With Psoriasis

Active Plaque Psoriasis

United States, Germany, Israel
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer

Platinum Resistant Ovarian Cancer

United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Unknown

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Advanced and/or Metastatic Solid Organ Cancer

United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers

Biomarker

United Kingdom
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

Glioblastoma Multiforme

Israel, United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) (GLOBE)

Glioblastoma

United States, Israel, Canada
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis

Ulcerative Colitis

Poland, Bulgaria, Hungary
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis

Psoriasis

Germany, Israel, Poland, Spain
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Juan P. Alderuccio, MD
ADC Therapeutics S.A.

Recruiting

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

United States
Mayur Narkhede
ADC Therapeutics S.A.

Recruiting

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States

Clinical Trials Sponsored by ASC Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations